GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00194396 | Liver | NAFLD | aromatic compound catabolic process | 102/1882 | 467/18723 | 2.29e-14 | 1.91e-11 | 102 |
GO:19013616 | Liver | NAFLD | organic cyclic compound catabolic process | 105/1882 | 495/18723 | 7.04e-14 | 5.15e-11 | 105 |
GO:00442707 | Liver | NAFLD | cellular nitrogen compound catabolic process | 93/1882 | 451/18723 | 1.04e-11 | 4.34e-09 | 93 |
GO:00467006 | Liver | NAFLD | heterocycle catabolic process | 92/1882 | 445/18723 | 1.16e-11 | 4.52e-09 | 92 |
GO:00108765 | Liver | NAFLD | lipid localization | 79/1882 | 448/18723 | 4.75e-07 | 2.92e-05 | 79 |
GO:00068694 | Liver | NAFLD | lipid transport | 71/1882 | 398/18723 | 1.16e-06 | 5.59e-05 | 71 |
GO:0015850 | Liver | NAFLD | organic hydroxy compound transport | 50/1882 | 284/18723 | 6.01e-05 | 1.32e-03 | 50 |
GO:00030182 | Liver | NAFLD | vascular process in circulatory system | 46/1882 | 263/18723 | 1.36e-04 | 2.58e-03 | 46 |
GO:0015721 | Liver | NAFLD | bile acid and bile salt transport | 10/1882 | 30/18723 | 4.67e-04 | 6.74e-03 | 10 |
GO:01501043 | Liver | NAFLD | transport across blood-brain barrier | 17/1882 | 87/18723 | 5.46e-03 | 4.20e-02 | 17 |
GO:00102322 | Liver | NAFLD | vascular transport | 17/1882 | 88/18723 | 6.15e-03 | 4.61e-02 | 17 |
GO:190136111 | Liver | Cirrhotic | organic cyclic compound catabolic process | 213/4634 | 495/18723 | 1.58e-19 | 3.67e-17 | 213 |
GO:001943911 | Liver | Cirrhotic | aromatic compound catabolic process | 202/4634 | 467/18723 | 6.93e-19 | 1.28e-16 | 202 |
GO:004427011 | Liver | Cirrhotic | cellular nitrogen compound catabolic process | 195/4634 | 451/18723 | 2.99e-18 | 4.94e-16 | 195 |
GO:004670011 | Liver | Cirrhotic | heterocycle catabolic process | 192/4634 | 445/18723 | 7.17e-18 | 1.12e-15 | 192 |
GO:001087611 | Liver | Cirrhotic | lipid localization | 147/4634 | 448/18723 | 6.24e-05 | 7.12e-04 | 147 |
GO:000686911 | Liver | Cirrhotic | lipid transport | 128/4634 | 398/18723 | 4.54e-04 | 3.69e-03 | 128 |
GO:0006787 | Liver | Cirrhotic | porphyrin-containing compound catabolic process | 8/4634 | 12/18723 | 2.59e-03 | 1.53e-02 | 8 |
GO:0033015 | Liver | Cirrhotic | tetrapyrrole catabolic process | 8/4634 | 12/18723 | 2.59e-03 | 1.53e-02 | 8 |
GO:0033013 | Liver | Cirrhotic | tetrapyrrole metabolic process | 24/4634 | 59/18723 | 5.06e-03 | 2.62e-02 | 24 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLCO2B1 | SNV | Missense_Mutation | novel | c.532N>A | p.Ser178Thr | p.S178T | | protein_coding | tolerated(0.43) | possibly_damaging(0.69) | TCGA-A2-A3XV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
SLCO2B1 | SNV | Missense_Mutation | rs769193802 | c.1245N>G | p.Cys415Trp | p.C415W | | protein_coding | deleterious(0) | possibly_damaging(0.882) | TCGA-AN-A0XR-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
SLCO2B1 | SNV | Missense_Mutation | | c.556N>A | p.Leu186Met | p.L186M | | protein_coding | tolerated(0.24) | benign(0.248) | TCGA-AO-A0J3-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamide | SD |
SLCO2B1 | SNV | Missense_Mutation | rs750167927 | c.497N>T | p.Ser166Leu | p.S166L | | protein_coding | tolerated(0.36) | benign(0.007) | TCGA-D8-A1XS-01 | Breast | breast invasive carcinoma | Male | <65 | III/IV | Chemotherapy | adriamycin+cyclophosphamide | SD |
SLCO2B1 | SNV | Missense_Mutation | | c.1834N>T | p.Met612Leu | p.M612L | | protein_coding | tolerated(0.77) | benign(0.275) | TCGA-E2-A15O-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | PD |
SLCO2B1 | insertion | In_Frame_Ins | novel | c.1257_1258insGAACAAGGGCCAGGCATAGTGGCTCACGTC | p.Pro419_Ser420insGluGlnGlyProGlyIleValAlaHisVal | p.P419_S420insEQGPGIVAHV | | protein_coding | | | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
SLCO2B1 | deletion | In_Frame_Del | | c.1080_1109delNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN | p.Arg362_Pro371del | p.R362_P371del | | protein_coding | | | TCGA-C8-A12L-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLCO2B1 | SNV | Missense_Mutation | rs551118953 | c.154G>A | p.Val52Ile | p.V52I | | protein_coding | deleterious(0.04) | benign(0.078) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLCO2B1 | SNV | Missense_Mutation | novel | c.1516C>T | p.Pro506Ser | p.P506S | | protein_coding | tolerated(0.49) | benign(0.012) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD |
SLCO2B1 | SNV | Missense_Mutation | | c.538N>C | p.Tyr180His | p.Y180H | | protein_coding | tolerated(0.58) | benign(0.003) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
11309 | SLCO2B1 | TRANSPORTER, DRUGGABLE GENOME | inhibitor | 178101291 | | |
11309 | SLCO2B1 | TRANSPORTER, DRUGGABLE GENOME | | ISOSILYBIN A | ISOSILYBIN A | 23401473 |
11309 | SLCO2B1 | TRANSPORTER, DRUGGABLE GENOME | | SCUTELLARIN | SCUTELLARIN | 22822035 |
11309 | SLCO2B1 | TRANSPORTER, DRUGGABLE GENOME | | pravastatin | PRAVASTATIN | |
11309 | SLCO2B1 | TRANSPORTER, DRUGGABLE GENOME | | SILYCHRISTIN | SILICRISTIN | 23401473 |
11309 | SLCO2B1 | TRANSPORTER, DRUGGABLE GENOME | | atorvastatin | ATORVASTATIN | |
11309 | SLCO2B1 | TRANSPORTER, DRUGGABLE GENOME | | ROSIGLITAZONE | ROSIGLITAZONE | 18314419 |
11309 | SLCO2B1 | TRANSPORTER, DRUGGABLE GENOME | | HUMAN CHORIONIC GONADOTROPIN | | 17049229 |
11309 | SLCO2B1 | TRANSPORTER, DRUGGABLE GENOME | inhibitor | 178101454 | SILDENAFIL | |
11309 | SLCO2B1 | TRANSPORTER, DRUGGABLE GENOME | | fexofenadine | FEXOFENADINE | 21280267 |